An Expanded Access Program for AM0010 (Pegilodecakin)

• Conditions: Ovarian Cancer; Pancreatic Carcinoma; Breast Cancer; Non-small Cell Lung Carcinoma; Solid Tumors; Melanoma; Prostate Cancer; Colorectal Carcinoma; Renal Cell Carcinoma

• Registration Number: NCT03554434
• Lead Sponsor: Eli Lilly and Company

Brief Summary

This is an Expanded Access Program (EAP) available to patients who have advanced cancers, who have failed or progressed on standard of care systemic therapy and do not qualify for ongoing clinical trials.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-05-31
• Study First Submitted QC: 2018-05-31
• Study First Posted: 2018-06-13
• Status Verified: 2020-02
• Last Update Submitted: 2020-02-27
• Last Update Posted: 2020-03-02

Recruitment & Eligibility

• Status: NO_LONGER_AVAILABLE
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: EXPANDED_ACCESS
• Study Design: Not specified